Top Markets
Coin of the day
Antibe Therapeutics Inc. Antibe Therapeutics Inc.

Antibe Therapeutics Inc.

ATE
Rank in Stocks #32097
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Share Price
$0.21483059
Last synced: 2024-05-07
Market Cap
$11.13M
Change (1 day)
0.34%
Change (1 year)
0.00%
Country
CA
Trade Antibe Therapeutics Inc. (ATE)

Category

Stock split history for Antibe Therapeutics Inc. (ATE)
Antibe Therapeutics Inc. stock (symbol: ATE) underwent a total of 0 stock splits.
The most recent stock split occurred on Aug 18, 2026.
One ATE share bought prior to Aug 18, 2026 would equal to 0 ATE shares today.
Stock split list
Year Split Multiple Cumulative Multiple
Not enough data for the provided dates.
Stock splits for similar companies or competitors
Company Number of stock splits Cumulative Multiple Country
9 x285
US
9 x162
US
7 x127
IE
2 x4
US
3 x12
US